The National Institute on Aging (NIA) intends to modify an existing contract with the University of Exeter to extend the ordering period by one year, through August 1, 2027, for clinical evaluation of a drug formulation in early mild Alzheimer’s disease and mild to moderate traumatic brain injury. The contract involves phase 1/2 clinical trials, including multiple ascending dose studies and longer-term efficacy analysis, with services performed at the contractor’s facilities in the United Kingdom. No budget amounts are specified in the notice. The extension allows completion of planned task orders, including brain imaging, cognitive assessments, and blood sample analysis. This is a non-competitive action, but interested parties may submit capability statements by the specified response timeline.